SK Biopharmaceuticals Co., Ltd. Statistics
Want to see KR:326030 full AI Analyst Report?
SK Biopharmaceuticals Co., Ltd. (326030) Stock Statistics & Valuation Metrics
Total Valuation
SK Biopharmaceuticals Co., Ltd. has a market cap or net worth of KRW 6.97T. The enterprise value is KRW 5.40T.
- Market Cap
- KRW 6.97T
- Enterprise Value
- KRW 5.40T
Share Statistics
SK Biopharmaceuticals Co., Ltd. has 78,313,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 78,313,250
- Owned by Insiders
- ―
- Owned by Institutions
- 4.65%
Financial Efficiency
SK Biopharmaceuticals Co., Ltd.’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is 22.17%.
- Return on Equity (ROE)
- 0.33
- Return on Assets (ROA)
- 0.22
- Return on Invested Capital (ROIC)
- 22.17%
- Return on Capital Employed (ROCE)
- 0.23
- Revenue Per Employee
- 2.93B
- Profits Per Employee
- 1.11B
- Employee Count
- 241
- Asset Turnover
- 0.59
- Inventory Turnover
- 0.55
Valuation Ratios
The current PE Ratio of SK Biopharmaceuticals Co., Ltd. is 18.31. SK Biopharmaceuticals Co., Ltd.’s PEG ratio is 1.24.
- PE Ratio
- 18.31
- PS Ratio
- 7.25
- PB Ratio
- 6.43
- Price to FCF
- 24.63
- Price to Operating Cash Flow
- 23.92
- PEG Ratio
- 1.24
Income Statement
In the last 12 months, SK Biopharmaceuticals Co., Ltd. had revenue of 706.74B and earned 266.95B in profits. Earnings per share was 3408.75.
- Revenue
- 706.74B
- Gross Profit
- 651.67B
- Operating Income
- 203.94B
- Pretax Income
- 150.88B
- Net Income
- 266.95B
- EBITDA
- 220.89B
- Earnings Per Share (EPS)
- 3408.75
Cash Flow
In the last 12 months, operating cash flow was 251.61B and capital expenditures -7.82B, giving a free cash flow of 243.78B billion.
- Operating Cash Flow
- 251.61B
- Free Cash Flow
- 243.78B
- Free Cash Flow per Share
- 3487.80
Dividends & Yields
SK Biopharmaceuticals Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.06%
- Earnings Yield
- 5.67%
Stock Price Statistics
- Beta
- 0.14
- 52-Week Price Change
- -32.26%
- 50-Day Moving Average
- 78228.00
- 200-Day Moving Average
- 89783.50
- Relative Strength Index (RSI)
- 68.12
- Average Volume (3m)
- 159.34K
Important Dates
SK Biopharmaceuticals Co., Ltd. upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Feb 10, 2027
- Ex-Dividend Date
- ―
Financial Position
SK Biopharmaceuticals Co., Ltd. as a current ratio of 2.31, with Debt / Equity ratio of 6.02%
- Current Ratio
- 2.31
- Quick Ratio
- 1.97
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.17
- Interest Coverage Ratio
- 26.52
Taxes
In the past 12 months, SK Biopharmaceuticals Co., Ltd. has paid -102.37B in taxes.
- Income Tax
- -102.37B
- Effective Tax Rate
- -0.68
Enterprise Valuation
SK Biopharmaceuticals Co., Ltd. EV to EBITDA ratio is 22.25, with an EV/FCF ratio of 23.17.
- EV to Sales
- 6.82
- EV to EBITDA
- 22.25
- EV to Free Cash Flow
- 23.17
- EV to Operating Cash Flow
- 22.51
Balance Sheet
SK Biopharmaceuticals Co., Ltd. has KRW 381.87B in cash and marketable securities with KRW 48.83B in debt, giving a net cash position of KRW 333.05B billion.
- Cash & Marketable Securities
- KRW 381.87B
- Total Debt
- KRW 48.83B
- Net Cash
- KRW 333.05B
- Net Cash Per Share
- KRW 4,252.74
- Tangible Book Value Per Share
- KRW 12.34K
Margins
Gross margin is 92.32%, with operating margin of 37.65%, and net profit margin of 41.07%.
- Gross Margin
- 92.32%
- Operating Margin
- 37.65%
- Pretax Margin
- 34.75%
- Net Profit Margin
- 41.07%
- EBITDA Margin
- 31.06%
- EBIT Margin
- 29.37%
Analyst Forecast
The average price target for SK Biopharmaceuticals Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 37.40%
- EPS Growth Forecast
- 18.94%
Scores
- Smart Score
- ―
- AI Score
- 69

